What is Adial Pharmaceuticals's market cap?

Adial Pharmaceuticals (ADIL) has a market capitalization of $6.5M and trades on NASDAQ.

Who are Adial Pharmaceuticals's competitors?

Adial Pharmaceuticals's key competitors include Alkermes, Indivior Pharmaceuticals, Inc. Common Stock, Altimmune, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Adial Pharmaceuticals partner with?

Adial Pharmaceuticals's notable partners include Molteni Farmaceutici, University of Virginia Patent Foundation, Ipsos-Insight LLC.

What subsidiaries does Adial Pharmaceuticals have?

Adial Pharmaceuticals's subsidiaries include Purnovate, Inc..

Where is Adial Pharmaceuticals headquartered?

Adial Pharmaceuticals is headquartered in United States of America and employs approximately 7 people. It has been publicly traded since 2018.

Adial Pharmaceuticals

ADIL

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in therapeutics for addiction and related disorders.

Market cap

$6.46M-13.7%

Table of contents

Earnings

Q1 2026 report

May 8, 2026

EPS-$1.48Beat by $1.25

Read the full report

Next report

Aug 12, 2026 (In 1 week)

EPS estimate-$1.02

Competitors

By market cap

Alkermes$8.5B+90.3%

Indivior Pharmaceuticals, Inc. $4.8B+125%

Viking Therapeutics$3.9B+6.2%

Altimmune$581.5M+87.2%

Nutriband$35.9M-57.2%

Adial Pharmaceuticals$6.5M-32.5%

Alaunos Therapeutics$4.6M+2.2%

CDT

Conduit Pharmaceuticals$1.9M-59.0%

By revenue growth

Alkermes+10.8%

Indivior Pharmaceuticals, Inc. +10.3%

By net margin

Indivior Pharmaceuticals, Inc. 19.44%+20.0pp

Alkermes3.97%-19.2pp

Altimmune-214,860.98%—

Profile

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in therapeutics for addiction and related disorders. The company's lead candidate, AD04, is a genetically targeted treatment for Alcohol Use Disorder (AUD) designed to support harm reduction rather than mandatory abstinence. Their value proposition centers on a precision medicine approach using a companion diagnostic genetic test to identify patients most likely to respond to treatment.

Competitive position

Adial is a pioneer in genetically targeted AUD treatment, utilizing a low-dose ondansetron formulation protected by a robust patent estate extending potentially to 2045.

GeographiesUnited States, Europe, United Kingdom

Customer segmentsPatients, Healthcare Providers, Strategic Partners

Business modelResearch and Development, Licensing, Precision Medicine

SuppliersUniversity of Virginia Patent Foundation, Contract Research Organizations, Active Pharmaceutical Ingredient Manufacturers, Statistical Consulting Groups

CustomersPharmaceutical Commercialization Partners, Hospitals and Clinics, Specialty Pharmacies

CountryUnited States of America

Listed2018

Employees7.0

CEOCary John Claiborne

SectorHealthcare

IndustryBiotechnology

Websiteadialpharma.com

FilingsSEC EDGAR

Questions, answered.

What is Adial Pharmaceuticals's market cap?: Adial Pharmaceuticals (ADIL) has a market capitalization of $6.5M and trades on NASDAQ.
Who are Adial Pharmaceuticals's competitors?: Adial Pharmaceuticals's key competitors include Alkermes, Indivior Pharmaceuticals, Inc. Common Stock, Altimmune, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Adial Pharmaceuticals partner with?: Adial Pharmaceuticals's notable partners include Molteni Farmaceutici, University of Virginia Patent Foundation, Ipsos-Insight LLC.
What subsidiaries does Adial Pharmaceuticals have?: Adial Pharmaceuticals's subsidiaries include Purnovate, Inc..
Where is Adial Pharmaceuticals headquartered?: Adial Pharmaceuticals is headquartered in United States of America and employs approximately 7 people. It has been publicly traded since 2018.